Form 4: Journey Medical Corp Director Herskowitz Receives Stock Units
SEC Form 4
Director Neil Herskowitz of Journey Medical Corp reports acquisition of restricted stock units.
Summary
- On July 8, 2024, Neil Herskowitz, a director of Journey Medical Corp, was granted 9,728 restricted stock units (RSUs) under the company's 2015 Stock Plan.
- These RSUs will vest in full on July 8, 2025.
- Following the transaction, Herskowitz beneficially owns 81,445 shares, including restricted stock units that vest over various time periods.
Sentiment
Score: 6
Explanation: The sentiment is neutral as it reflects a standard transaction of granting stock units to a director. It's a routine part of executive compensation.
Positives
- The grant of restricted stock units aligns the director's interests with the company's performance and shareholder value.
Future Outlook
The vesting of the restricted stock units on July 8, 2025, represents a future event that could impact the director's holdings.
Industry Context
This filing is a routine disclosure related to executive compensation and is common in the pharmaceutical industry to incentivize and retain key personnel.
Stakeholder Impact
- The granting of restricted stock units could potentially align the director's interests more closely with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 07/08/2024 | Date of transaction: Grant of 9,728 restricted stock units. |
| 07/08/2025 | Vesting date for the 9,728 restricted stock units. |
| 07/10/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.